ReviewJournal of clinical medicine2019
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 248 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
248 citing papers in PubMed, 488 citations in OpenAlex.
- Efficacy and safety of fruquintinib combined with albumin-bound paclitaxel as second-line therapy for advanced gastric cancer following failure of PD-1 inhibitor-containing treatment (TACTIC GC-01): A phase II single-arm study.International journal of cancer · 2026Trial
- Mesenchymal stromal/stem cells in tumour initiation, progression and therapy.Nature reviews. Cancer · 2026Review
- PSMD4 promotes malignant phenotypes and is associated with angiogenesis-related signaling and immune remodeling in hepatocellular carcinoma.Discover oncology · 2026Article
- Oral Poly(N-oxide) zwitterionic nanoplatform for Gambogenic Acid Enhances Mucosal penetration for potentiated anti-angiogenic therapy.International journal of pharmaceutics: X · 2026Article
- The Niche Awakens: Comprehension of Cancer Stem Cells' Microenvironment to Plan New Therapeutic Strategies.Cells · 2026Review
- (Molecules (Basel, Switzerland) · 2026Article
- Tumor Anti-Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment.Cancer medicine · 2026Review
- Coffee Consumption and Its Potential Implications for Digestive Tract Carcinogenesis.Current nutrition reports · 2026Review
- The Effect of Cannabidiol on Cancer-Pathway Genes in Doxorubicin-Sensitive and Resistant Breast Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Circadian-driven transcriptional programs govern metastatic progression.Cancer biology & medicine · 2026Review
- Chlorogenic acid suppresses angiogenesis in 4T1 breast tumorsResearch in pharmaceutical sciences · 2026Article
- Natural Products Targeting Angiogenesis and Tumor Microenvironment in Gastrointestinal Malignancies.Cells · 2026Review
- The impact of lipid metabolism remodeling in the tumor microenvironment on angiogenesis.Discover oncology · 2026Review
- Extracellular Vesicles and Endocrine Disruption: How Environmental Pollutants Modulate the Loading and Release of Extracellular Vesicles for Cancer Promotion and Progression.International journal of molecular sciences · 2026Review
- Enhancing Cancer Therapy with Hyperthermia: Synergistic Effects with Natural Compounds and Conventional Treatments.International journal of molecular sciences · 2026Review
- Gold nanoparticles incorporating rutin hydrate for targeting oxidative stress-driven neurodegeneration.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
- Targeting Monocytes and Their Derivatives in Ovarian Cancer: Opportunities for Innovation in Prognosis and Therapy.Cancers · 2026Review
- Endothelial dysfunction determines vascular mechanisms of metastatic progression in breast cancer.Discover oncology · 2026Review
- Article
- Efficacy and safety analysis of PD-1 inhibitors combined with chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma.Frontiers in immunology · 2026Article
188 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis is the process through which novel blood vessels are formed from pre-existing ones and it is involved in both physiological and pathological processes of the body. Furthermore, tumor angiogenesis is a crucial factor associated with tumor growth, progression, and metastasis. In this manner, there has been a great interest in the development of anti-angiogenesis strategies that could inhibit tumor vascularization. Conventional approaches comprise the administration of anti-angiogenic drugs that target and block the activity of proangiogenic factors. However, as their efficacy is still a matter of debate, novel strategies have been focusing on combining anti-angiogenic agents with chemotherapy or immunotherapy. Moreover, nanotechnology has also been investigated for the potential of nanomaterials to target and release anti-angiogenic drugs at specific sites. The aim of this paper is to review the mechanisms involved in angiogenesis and tumor vascularization and provide an overview of the recent trends in anti-angiogenic strategies for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.